drugset / Trial / NCT06043323
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
To learn about the safety of a drug called axicabtagene ciloleucel given in combination with radiation therapy to patients with relapsed/refractory FL.
Timeline
- Start
- 2024-01-08
- Primary completion
- 2026-09-01
- Completion
- 2028-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axicabtagene Ciloleucel | Cell therapy | — | Intravenous |
| Background | Acetaminophen | Small molecule | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Diphenhydramine | Unknown | — | Intravenous |
| Background | Fludarabine | Small molecule | — | Intravenous |
| Background | Prednisone | Other / unclassified | — | Intravenous |